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subunit-	containing	NMDARs	has	 recently	 attracted	 significant	 attention	as	poten-
tial	 pharmacological	 targets,	 with	 emphasis	 on	 the	 functional	 properties	 of	 allos-
teric	 antagonists.	We	used	primary	cultures	 from	chicken	embryo	 forebrain	 (E10),	
expressing	 native	 GluN2B-	containing	 NMDA	 receptors	 as	 a	 novel	 model	 system.	
Comparing	the	 inhibition	of	calcium	 influx	by	well-	known	GluN2B	subunit-	specific	
allosteric	 antagonists,	 the	 following	 rank	 order	 of	 potency	 was	 found:	 EVT-	
101	 (EC50	22	±	8	nmol/L)	>	Ro	25-	6981	 (EC50	60	±	30	nmol/L)	>	 ifenprodil	 (EC50 
100	±	40	nmol/L)	>	eliprodil	(EC50	1300	±	700	nmol/L),	similar	to	previous	observa-




amino	 terminal	domain.	We	 found	 that	Ro	04-	5595	was	predicted	 to	bind	 the	 re-
cently	discovered	EVT-	101	binding	site,	not	the	ifenprodil-	binding	site.	The	EVT-	101	
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1  | INTRODUC TION
The	N-	methyl-	d-	aspartate	 (NMDA)	 receptors	 are	 found	 in	 all	 brain	
regions	and	are	involved	in	synaptic	plasticity,	learning,	and	memory.1 
They	 belong	 to	 a	 subfamily	 of	 excitatory	 glutamate	 receptors	 that	





GluN2A,	GluN2B,	GluN2C,	 and	GluN2D,	 and	 the	 structure	 can	be	
homo-	or	heterotetrameric	with	respect	to	the	different	GluN2	sub-
units.3 The receptor distribution and composition are dynamic and 
change during development and in response to sensory input.4
Neurodegenerative	 diseases	 such	 as	 Parkinson's	 disease,	
Alzheimer's	 disease,	 and	 epilepsy	 are	 associated	 with	 pathological	
changes	in	the	assembly	and	location	of	NMDA	receptors.5-7 Changes 




severe psychotomimetic side effects observed when administrating 
unspecific	 total	 channel	blockers	 such	as	MK-	801	and	ketamine	 to	
humans	 and	 animal	models,12 indicate a need for new partial and/
or	subtype-	specific	antagonists.	To	develop	new	drug	candidates,	it	
is	essential	to	understand	the	receptor	binding	mechanisms	and	ex-
plore the conformational space of the receptor binding sites.
The	amino	terminal	domain	(ATD)	of	the	subunits	contains	bind-
ing	 sites	 for	 allosteric	 compounds,	 such	 as	 the	 synthetic	GluN2B-	
specific	 antagonists	 eliprodil,	 Ro	 25-	6981,	 and	 ifenprodil.13-16 
Recently,	an	x-	ray	crystal	structure	of	the	GluN1	and	GluN2B	ATD	
dimer	in	complex	with	ifenprodil	was	resolved.17	However,	ifenprodil	
displays unspecific binding to sigma opioid receptors and mono-
amine	 receptors,18-20	 causes	 behavioral	 toxicity21 and it is readily 




EVT-	101	 (another	 GluN2B	 antagonist)	 binds	 at	 the	 same	 GluN1/
GluN2B	interface	as	ifenprodil,	but	occupies	an	overlapping	and	less	
explored	 binding	 site.17	 The	 GluN2B-	specific	 allosteric	 antagonist	
HON0001	(structurally	similar	to	Ro	04-	5595)	has	also	been	shown	
to	have	a	potent	dose-	dependent	oral	analgesic	activity	in	rats,	with	
less side effects and higher receptor specificity than ifenprodil24 and 
it	has	been	predicted	to	interact	with	the	EVT-	101	binding	site.17 In 
this	paper,	 ligands	predicted	to	bind	the	 ifenprodil-	binding	site	are	
denoted	A-	ligands,	while	 those	predicted	 to	bind	 the	EVT	site	are	
named	B-	ligands.
The	 NMDA	 receptor	 is	 evolutionarily	 conserved	 across	 spe-
cies.25	Many	 studies	 have	 therefore	 used	 overexpressed	 chimeric	
NMDA	 receptors	with	 constituents	 from	Rattus norvegicus	 (R. nor-
vegicus),	Xenopus laevis	 (X. laevis),	or	Homo sapiens	 (H. sapiens).26-28 
In vitro cultured neurons from the developing chicken brain was 
recently suggested as a suitable model for nonclinical drug testing.29 
Chicken	forebrain	culture	expresses	native,	functional	NMDA	recep-
tors	with	a	high	proportion	of	GluN2B	subunits,	features	that	make	




investigated by docking studies and molecular dynamics simulations 
using	experimental	structures	of	GluN1/GluN2B	ATD,	and	the	pre-
dicted binding data were compared to functional results. We also 
investigated amino acids critical for ligand binding by in silico muta-
tion	studies	and	found	that	the	residues	that	differentiate	the	EVT-	




When comparing ligands that are predicted to bind to the ifenprodil 
site,	 it	 appeared	 that	 the	 less	potent	allosteric	antagonist	eliprodil	
failed	 to	 interact	 with	 residues	 GluN1Ser132,	 GluN2BTyr175	 and	




similar,	 while	 the	 EVT-	101	 binding	 site	 appears	 to	 accommodate	
more	structurally	diverse	 ligands	and	binding	poses,	which	 is	 sup-
ported by earlier work.17








formaldehyde,	 and	 anti-	β-	actin	 antibody	 were	 purchased	 from	
Sigma-	Aldrich©	 (now	 part	 of	 Merck,	 USA).	 Triton™	 X-	100,	 Fura-	2	
AM	 cell	 permeant,	 and	 ProLong™	 Gold	 Antifade	 Mountant	 with	
DAPI	were	obtained	from	ThermoFisher™	(USA),	while	anti-	GluN2B	
came	 from	 Abcam	 (Cambridge,	 UK).	 Donkey	 anti-	rabbit	 IgG-	HRP	
was	obtained	from	Santa	Cruz	Incorporated	(Santa	Cruz,	CA),	while	
Luminata	Crescendo	and	Classico	Western	HRP	substrate	and	anti-	
NeuN	 antibody	 came	 from	Merck	Millipore	 (Temecula,	 CA).	 FITC	
A109,	anti-	mouse	originated	from	Chemicon	International	Inc.	(later	
acquired	 by	 Merck	 Millipore),	 and	 goat	 anti-	mouse	 IgG-	HRP	 was	
bought	from	Biorad	(Hercules,	CA).
2.2 | Animals
Fertilized	eggs	 (Gallus gallus)	 from	different	hatches	were	purchased	
from	Nortura	Samvirkekylling	(Våler,	Norway).	The	eggs	were	incubated	




by	 observing	 spontaneous	 movement.	 Embryos	 were	 sacrificed	 at	
embryonic	day	10	 (E10),	 and	 sex	determination	was	not	performed.	




housing and elicit fewer allergies than murine animal models.30 It is also 
easier to predict the number of embryos obtained compared to rat or 
mice,	and	the	hen	is	exempted	from	experiments.	Thus,	their	use	is	in	
accordance with the 3Rs principles of animal research.
2.3 | Chicken embryo forebrain cultures
The eggs were submerged in crushed ice for 7 minutes to anesthe-
tize	the	embryos	before	decapitation.	The	forebrain	was	surgically	
removed,	and	the	meninges	were	discarded.	The	tissue	was	homog-
enized	by	 chopping	with	 a	 scalpel	 before	 trypsination	 in	 buffered	
solutions as previously described.30,31 Cells were suspended in 
DMEM	supplemented	with	1%	N-	2,	100	U/mL	penicillin	and	0.1	mg/






2.4 | Transfection of control HEK- 293 cells
Human	 embryonic	 kidney	 cells	 (HEK-	293	 cells,	 CRL-	1573™	 from	
ATCC®,	USA)	were	maintained	 in	DMEM	supplemented	with	 10%	
FBS,	100	U/mL	penicillin	and	0.1	mg/mL	streptomycin	and	4	mmol/L	
l-	glutamine.	 Experiments	 were	 performed	 after	 passage	 num-














Chicken	 embryo	 forebrain	 cultures	 (harvested	 at	 day	 in	 vitro	 1	
[DIV1])	and	HEK-	293	cell	cultures	were	washed	twice	with	ice-	cold	
PBS	(4°C)	and	harvested	in	2%	SDS	(in	PBS)	added	the	following	pro-








same	 protease	 inhibitors	 as	 described	 above,	 and	 homogenized	
using	a	motorized	pellet	pestle.	TE	with	SDS	(final	concentration	
2%)	was	added	to	 the	sample	before	 further	homogenization	by	




to	 a	 precast	 10-	well	 polyacrylamide	 Mini-	Protean	 Tris-	Glycine-	
extended	 (TGX™)	 gel	 (BioRad,	 Germany).	 After	 electrophore-
sis,	 the	 proteins	were	 transferred	 to	 a	 nitrocellulose	membrane	
(TransBlot®Turbo™;	 BioRad,	 Germany)	 which	 was	 blocked	 with	
5%	 dry	 skimmed	 milk	 in	 1%	 Tween-	Tris-	buffered	 saline	 solu-
tion	 (TBS-	T)	 for	 1	 hour	 at	 room	 temperature	 (RT).	 The	 primary	
GluN2B	 antibody	was	 diluted	 in	 5%	 dry	 skimmed	milk	 in	 TBS-	T	
to a concentration of 1:1000 and added to the membranes which 
were then incubated for 24 hours at 4°C. The membranes were 






sessed by immunostaining with β-	actin	antibody	and	anti-	mouse	
secondary	 antibody.	 The	data	were	 analyzed	 using	 ImageJ	 soft-








before	 blocking	 with	 5%	 dry	 skimmed	milk	 in	 1%TBS/Tween	 for	
30	minutes	at	RT.	After	washing	twice	with	cold	PBS,	the	neuronal	
marker	antibody	NeuN	was	diluted	in	PBS	(1:100)	and	100	μL	was	
added to the dishes and incubated at 4°C for 12 hours. The dishes 
were	washed	three	times	with	cold	PBS	before	400	μL	of	secondary	
FITC	antibody	diluted	in	5%	dry	skimmed	milk	in	1%TBS/Tween	was	
added at a concentration of 1:250 and left to incubate in the dark 
for 1 hour at RT. The cells were mounted with the nuclear marker 
DAPI	and	visualized	with	fluorescence	microscopy	(Eclipse	TE300;	
Nikon,	Japan).
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2.7 | Calcium influx measurement
The procedure was similar to that previously described by Ring 
et al34	Cells	were	plated	in	poly-	l-	lysine	coated	96-	well	black	plates	
with	clear	glass	bottom	(Corning®	CellBIND®)	and	each	well	was	in-
cubated with 4 μmol/L	fluorescent	calcium	(Ca2+)	indicator	Fura-	2	at	
37°C,	5%	CO2 for 45 minutes.






CLARIOstar®	 plate	 reader	 (BMG	 Labtech,	 Germany).	 Intracellular	
Ca2+	 changes	were	 expressed	 as	 changes	 in	 340/380	 nm	 fluores-
cence emission ratio. The wash buffer was then carefully replaced 





by subtracting the initial Ca2+	level	from	the	NMDA	stimulated	Ca2+ 
responses.	For	the	compound	EVT-	101,	additional	experiments	with	
a	lower	dose	range	(2	nmol/L	to	1	μmol/L)	were	included	due	to	the	








in	the	Protein	Data	Bank	 (PDB).36	Among	them	are	X. laevis/H. sa-
piens	 in	 complex	with	 ifenprodil	 and	 EVT-	101	 (PDB	 id:	 5EWJ	 and	
5EWM,	respectively)17,37 and X. laevis/R. norvegicus	in	complex	with	
Ro	25-	6981	(PDB	id:	3QEM).38	The	experimental	structures	contain	
two	dimers	with	each	dimer	consisting	of	the	GluN1	from	X. laevis 
(chain	A)	and	the	GluN2B	from	H. sapiens or R. norvegicus (chain	B).	
Two	different	 conformations	 of	 EVT-	101	binding	 pose	 can	be	ob-
served	in	the	crystal	structure,	depending	on	what	dimer	is	consid-
ered.	In	this	paper,	the	A	dimer	was	selected	for	molecular	modeling	
studies.	 The	 experimental	 structures	 (5EWJ,	 5EWM,	 and	 3QEM)	
were	prepared	in	Protein	Preparation	Wizard	feature	 in	Maestro39 
by	 assigning	 bond	 orders,	 adding	 hydrogen	 atoms,	 creating	 zero-	
order bonds to metal and disulfide bonds and building missing loops 
<20	amino	acids	(GluN1:	amino	acid	97-	101,	GluN2B:	amino	acid	53-	
62	 and	 54-	59	 for	H. sapiens and R. norvegicus,	 respectively)	 using	
Prime.40	 The	 large	 missing	 loop	 (186-	209	 located	 in	 GluN1)	 was	
not modeled as it was far from the ligand binding pocket and was 
therefore not considered to have any impact on the binding pocket. 






The	 chicken	 GluN1	 sequence	was	 retrieved	 from	UniProt	 (ID:	
Q4KXT1)29	while	the	chicken	GluN2B	sequence	was	retrieved	from	
the	predicted	target	sequence	with	BLAST	 (Basic	Local	Alignment	




ilar	 to	 the	GluN1	ATD	 sequence	 from	X. laevis,	 while	 the	 chicken	
GluN2B	 ATD	 has	 a	 95%	 sequence	 identity	 with	 the	 human	 and	
rat	GluN2B	ATD.	A	 sequence	 alignment	 between	human,	 rat,	 and	
chicken	Glun2B	subunits	can	be	found	in	supplementary	data	(Figure	
S1),	made	with	the	Clustal	Omega	multiple	sequence	alignment	pro-












The only difference close to the allosteric binding pockets of 
ifenprodil	 and	 EVT-	101	 (14.4	 and	 13.1	 Å,	 respectively),	 between	
the	 chimeric	 experimental	 structures	 and	 the	 chicken	 NMDA	 re-
ceptor,	 is	 a	 valine	 at	 position	 107	 in	 the	 chicken	GluN1	 sequence	
compared to an isoleucine in position 107 in the X. laevis	 GluN1	
sequence.	The	allosteric	binding	pocket	of	 the	chicken	NDMA	re-
ceptor	 (chicken_5EWJ	and	chicken_5EWM)	was	created	by	mutat-
ing the isoleucine residue in position 107 to valine in the chimeric 
X. laevis/H. sapiens and X. laevis/R. norvegicus	NMDA	receptor	crystal	
structure	(PDB	id:	5EWJ	and	5EWM	respectively).	The	comparison	
of	the	docking	poses	of	the	co-	crystallized	ligands	in	the	allosteric	
binding pocket of the chicken vs their binding pose in their respec-
tive	crystal	structure	did	not	reveal	any	relevant	differences	(Figure	
S1A,	in	supplemental	data).	Furthermore,	the	two	conformations	of	
EVT-	101	 binding	 pose	 observed	 in	 the	 crystal	 structure	 could	 be	
predicted	by	docking	with	similar	docking	scores	(Figure	S1B).	It	was	
therefore decided to use the crystal structures in further docking 
studies and molecular dynamics simulations.
2.9 | Ligand preparation and docking studies
The	docking	procedures	were	performed	in	Schrödinger's	Glide	soft-
ware.43 Receptor grid maps were generated for both crystal struc-
tures	 in	 complex	with	 ifenprodil	 and	 EVT-	101	 (PDB	 id:	 5EWJ	 and	
5EWM,	 respectively)	 using	 default	 settings44	 and	 co-	crystallized	
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ligands as the centroid of the map. Two overlapping allosteric bind-
ing	sites	have	been	described	for	the	GluN1/GluN2B	subunits:	the	
ifenprodil	 and	 the	EVT-	101	binding	pockets.17,38 In order to study 
the	ligand-	protein	interactions	of	the	ligands	used	in	vitro, the com-
plexes	GluN1/GluN2B:	ifenprodil,	GluN1/GluN2B:	Ro	25-	6981,	and	







Stroebel et al17	 reported	 that	 the	GluN1	residues	 leucine	135	and	
isoleucine	133	rotate	to	fill	the	empty	space	of	the	ifenprodil-	binding	
pocket	when	EVT-	101	 is	 co-	crystallized	with	 the	NMDA	 receptor,	
obstructing	 the	 binding	 pocket	 of	 ifenprodil.	 Hence,	 eliprodil	 and	
Ro	 04-	5595	 were	 docked	 into	 both	 chimeric	 X. laevis/H. sapiens 
NMDA	x-	ray	crystal	structures	using	the	virtual	screening	workflow.	
Standard precision was employed with retention of three docking 
poses	per	enantiomer	for	a	final	MM-	GBSA	calculation.	For	each	li-
gand,	 the	 complex	protein-	docking	pose	with	 the	best	MM-	GBSA	
score was chosen as input for the MD simulation.
Due	to	its	structural	similarity	with	Ro	04-	5595	and	interesting	
pharmacological	 properties,	 HON0001	 was	 compared	 to	 Ro	 04-	
















grator was selected and the bonded and close nonbonded interac-
tions were handled with a timestep of 2 fs while for far nonbonded 
interactions	the	timestep	was	set	to	6	fs.	A	cut-	off	of	9	Å	was	used	
for	the	short-	range	columbic	interactions.	The	trajectories	and	ener-








were mutated into alanine and their contribution to the free energy 
of	 binding	 (ΔG)	was	 analyzed	 by	 calculating	 the	 difference	 in	ΔG	




MacroModel	 software,47	with	OPLS3	 force	 field,	water	 as	 solvent	
and	extended	cut-	off.
2.11 | Analysis and statistics
Outlier	values	were	 tested	 for	by	 the	built-	in	 feature	 in	GraphPad	







3.1 | Cultures from chicken forebrain express 
GluN2B
Since chicken primary forebrain neuron cultures have not been 
described	before,	we	 immunostained	them	with	NeuN,	a	marker	
of most neurons that have reached a certain level of maturity. 
The	 fraction	 of	 NeuN-	positive	 cells	 was	 estimated	 to	 be	 40%	
relative	 to	 the	overall	 cell	number	 (DAPI-	stained	nuclei)	 at	DIV1	
(Figure	1A,B).
The	 presence	 of	 GluN2B	 was	 confirmed	 with	 western	 blot-
ting.	 Specificity	 of	 the	 GluN2B	 antibody	 was	 assessed	 in	 trans-
fected	 HEK-	293	 cells	 overexpressing	 the	 GluN2B	 subunit,	 shown	






level	of	GluN2B	protein	 in	 the	chicken	 forebrain	 increased	 rapidly	
from	E12	and	reached	a	plateau	at	E15	(Figure	1D).
3.2 | Functional properties of chicken NMDA 
receptors resemble their human and rat counterparts
Functional	 properties	 of	 the	NMDA	 receptor	 in	 chicken	 forebrain	
culture	were	tested	with	the	calcium	influx	assay	as	described	previ-
ously.34 It was shown that the receptor was activated by standard 
protocol	 concentrations	of	NMDA	and	glycine.	The	NMDA	recep-
tors in the cultures were assumed to contain a significant fraction of 
GluN2B	subunits	as	approximately	70%	of	the	calcium	influx	could	be	
blocked	by	the	GluN2B-	specific	allosteric	antagonists	Ro	25-	6981,	
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ifenprodil,	eliprodil,	and	EVT-	101,	at	concentrations	shown	to	elicit	
similar	 responses	 in	 rat	 and	human	NMDA	receptors	 (Table	1	and	
Figure	2A)17,48	and	that	the	calcium	influx	was	reduced	by	90%	by	
10 μmol/L	of	the	unspecific	NMDA	receptor	inhibitor	MK-	801.49,50 
The	 less-	explored	antagonist	Ro	04-	5595	showed	an	 IC50 value of 
<200	nmol/L.	The	differences	in	IC50 values between eliprodil and 
the	 other	 A-	ligands	were	 statistically	 significant:	 Eliprodil	 vs	 ifen-
prodil	and	eliprodil	vs	Ro	25-	6981	(*P	≤	0.05,	and	***P	≤	0.001,	re-
spectively,	shown	in	Figure	2B).	B-	ligands	EVT-	101	and	Ro	04-	5595	
gave significantly different IC50	 values	 when	 tested	 experimen-
tally	 in	 the	 chicken	 forebrain	 primary	 culture	 calcium	 influx	 assay	
(****P	<	0.0001,	Figure	2C).
3.3 | Computer modeling reveals conserved tertiary 
structure of chicken GluN1/GluN2B ATD
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ATD	provided	a	good	starting	point	for	making	a	homology	model	of	
the	chicken	GluN1/GluN2B	ATD	(Figure	S1).	Introducing	an	in	silico	






tures instead of the chicken homology model for studying the dy-
namics	of	ligand	interactions.	X-	ray	structures	are	regarded	as	both	
structurally and energetically more stable than homology models 
and	more	reliable	predictions	are	expected.
3.4 | Molecular dynamics simulations predict 
interactions between ligands and binding site residues
Our docking studies and molecular dynamic simulations supported 
that	 Ro	 25-	6981	 and	 ifenprodil	 shared	 the	 ifenprodil-	binding	 site	
and	 showed	 that	eliprodil	 interacted	with	 the	ATD	domain	via	 the	






ing	 site,	 sharing	 a	 hydrophobic	 pocket	 with	 the	 ifenprodil-	binding	
site.17	The	best	MM-	GBSA	score	for	Ro	04-	5595	was	−71.23	kcal/





3.4.1 | The common hydrophobic pocket
Docking indicated that a part of the binding pocket is common 
for all compounds. This region of the receptor is hydrophobic 
and	 includes	Tyr109	 and	Phe113	 in	GluN1,	 as	well	 as	 Ile111	 and	
Phe114	in	GluN2B	which	all	accommodate	an	aromatic	ring,	or	the	
interface toward the linker region of the ligands.51	 In	addition,	all	
ligands	were	predicted	to	 interact	with	GluN1Ile133	(Ro	25-	6981	
interacted	sporadically),	and	all	except	Ro	04-	5595	were	predicted	
to	 interact	with	GluN2BPhe176.	Molecular	 dynamics	 simulations	
suggested that all ligands formed nontransient interactions with 
GluN1Tyr109,	but	B-	ligands	were	predicted	to	have	the	most	sta-
ble	interaction	with	this	residue	(Figure	4A).	Mutating	Tyr109	into	
alanine and calculating the change in binding free energy did in-
deed	predict	a	more	substantial	drop	in	affinities	for	B-	ligands	than	
for	A-	ligands.	The	B-	ligands	were	also	predicted	to	 interact	more	
strongly	with	GluN1Phe113.	Despite	 that,	 alanine	mutation	 scan	
of	GluN1Phe113	predicted	quite	similar	changes	in	affinity	for	Ro	
25-	6981,	eliprodil	and	Ro	04-	5595,	while	 ifenprodil	and	EVT-	101	





Ro	 25-	6981.	 This	 was	 supported	 by	 alanine	 mutation	 scanning	
data,	predicting	the	largest	change	in	ΔG	for	Ro	04-	5995	when	mu-
tating	GluN2BPhe114	into	alanine	in	silico.
Ifenprodil,	 EVT-	101,	 and	 Ro	 04-	5595	were	 predicted	 to	 bind	
GluN1Ile133	 equally	 firmly,	 but	 with	 different	 bonding	 patterns.	





dicted	 to	 interact	with	 Ro	 25-	6981,	 ifenprodil	 and	 EVT-	101	 in	 a	
fairly	similar	manner,	while	eliprodil	displayed	a	very	stable	 inter-
action	 to	 the	 residue.	 Despite	 that,	 the	 affinities	 of	 Ro	 25-	6981	





Chicken (present work) Human48 Rat48,17
IC50 n IC50 n IC50 n
Ro	25-	6981 60	±	27 6 49 ± 8 8 42	±	6 4
Ifenprodil 103 ± 39 5 130 ± 10 6 110 ± 10 5
Eliprodil 1263	±	683 8 930 ± 140 4 780 ± 90 6
EVT-	101 22 ± 8 8 – – 12 ± 0.2 12
Ro	04-	5595 186	±	35 13 – – – –








specific allosteric antagonists across 
species
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3.4.2 | The ifenprodil- binding site
The	predicted	common	residues	for	the	A-	ligands	Ro	25-	6981,	ifen-







while eliprodil was only predicted to be loosely associated with this 
residue	 (Figure	 4C).	 Alanine	 scanning	 mutation	 showed	 minimal	
difference	 in	affinity	for	all	 three	 ligands,	as	they	 interact	primarily	
with	 the	 amino	 acid	backbone.	GluN1Leu135	displayed	 the	 largest	
amount	of	interaction	with	eliprodil	and	slightly	less	with	ifenprodil,	
while	 Ro	 25-	6981	was	 predicted	 to	 bind	GluN1Leu135	 to	 a	 lesser	
extent.	However,	the	predicted	affinities	were	similarly	affected	for	
all ligands when mutating the residue into alanine. Molecular dynam-
ics simulations predicted comparable interaction properties for all 
ligands	toward	GluN2BGlu110.	Alanine	mutation	scanning	supported	
this	 result	 giving	 quite	 similar	ΔG	 values,	 but	 with	 the	 largest	 de-
crease	in	affinity	for	eliprodil.	Eliprodil	was	anticipated	to	interact	the	
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F IGURE  3 Representation of the 
average binding mode of each ligand 
with display of important binding site 
residues in their respective average 
protein structure. The bright red band 
















Both	 Ro	 25-	6981	 and	 ifenprodil	 were	 predicted	 to	 bind	
GluN2BTyr175	and	GluN2BMet207,	although	 ifenprodil	displayed	a	
more	 stable	 interaction.	Both	 ligands	were	predicted	 to	have	 com-
parable	 loss	 of	 affinity	when	mutating	GluN2BTyr175	 into	 alanine,	
while	mutating	GluN2BMet207	 into	alanine	only	slightly	decreased	
the	 affinity	 of	 ifenprodil.	 Eliprodil	 and	 ifenprodil	were	 predicted	 to	
both	have	a	 stable	binding	 to	GluN2BGlu106.	Affinity	of	 ifenprodil	
to the binding site was predicted to be severely decreased by mu-
tating	 the	 residue	 to	alanine,	while	 the	affinity	of	eliprodil	was	 less	
affected,	suggested	to	be	caused	by	its	bond	type	(π-	π stack vs water 
bridge).	According	to	the	molecular	dynamics	simulations	Ro	25-	6981	
interacted	with	 two	 amino	 acid	 residues	 on	 its	 own:	GluN1Leu131	





F IGURE  3   continued
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F IGURE  4 Observed interactions between the ligands and the receptor during molecular dynamics simulations and comparison of 
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and	 GluN2BLeu205.	 Both	 were	 weak	 hydrogen	 bond	 interactions.	
Mutation of both residues into alanine was not predicted to have 
an	extensive	effect	on	the	affinity	of	Ro	25-	6981	to	the	binding	site	
(Figure	4D).
3.4.3 | The EVT- 101 binding site
The	amino	acid	residues	Asp113,	Asp136,	and	Pro177	(GluN2B)	
were	 predicted	 to	 interact	 with	 both	 B-	ligands	 Ro	 04-	5595	
and	 EVT-	101.	 GluN2BAsp113	 presumably	 displays	 a	 stable	 in-
teraction	 to	Ro	04-	5595	and	a	weaker	 connection	 to	EVT-	101.	
Introducing in silico mutations of asparagine to alanine had an 
opposite effect on the affinity of the two ligands. The affin-
ity	 of	 Ro	 04-	5595	 was	 lowered,	 while	 EVT-	101	 was	 predicted	




have	 interactions	with	 both	EVT-	101	 and	Ro	04-	5595,	 and	 the	
effect of changing the residue to alanine was relatively similar 
for	 both	 ligands.	 EVT-	101	 appears	 to	 have	 a	 hydrophobic	 in-
teraction	 with	 GluN2BMet134	 and	 a	 stable	 H-	bond	 with	 the	
backbone	of	GluN2BAla135	and	the	effect	on	the	affinity	of	the	
ligand when mutating the methionine residue was noticeable. Ro 
04-	5595	was	 predicted	 to	 interact	weakly	with	GluN2BLys137	
and	GluN2BAsp138,	mainly	through	water	bridges.	Alanine	mu-
tation scanning indicated an increase in ligand affinity when 
mutating both residues to alanine. The residues that were pre-
dicted	to	interact	with	both	EVT-	101	and	Ro	04-	5595	are	shown	
in	 Figure	 4E	 and	 the	 corresponding	 alanine	mutation	 scanning	
results	are	shown	in	Figure	4F.
Some of the residues that did not interact with the ligands still 
affected	 their	 affinities	 when	 running	 an	 alanine	 mutation	 scan,	
probably due to local conformational changes within the binding 
cavities	or	 indirect	effects.	The	residues	are	summarized	in	Figure	
S4	in	supplementary	data,	and	we	found	that	Ro	25-	6981,	ifenprodil,	





by alanine mutation scanning are included in the supplementary 
data	(Figure	S5).
4  | DISCUSSION








epitope.	 Compared	 to	 human	 and	 rat,	 the	 expression	 pattern	 of	
GluN2B	 in	 developing	 chicken	 forebrain	 follows	 a	 similar	 trajec-
tory.	However,	 the	decline	 in	GluN2B	protein	expression	appears	
to	 take	 place	 prenatally	 in	 chicken,	 as	 opposed	 to	 postnatally	 in	
human and rat. This may reflect a higher degree of relative maturity 
of	the	cortex	in	newly	hatched	chickens	compared	to	new-	born	rats	
or humans. This is an advantage when considering chicken embryos 
as	an	animal	model	for	NMDA	receptor	development,	as	it	enables	
easy access to study developmental processes occurring postna-
tally	in	other	research	animals,	while	the	chicken	is	still	contained	
within the egg.




brain	 cell	 culture	 contains	different	 cell	 types,	with	approximately	
40%	mature	neurons	 (NeuN	positive).	As	the	NMDA-	induced	Ca2+ 
influx	 could	be	 inhibited	70%	by	GluN2B-	specific	 antagonists	 and	
90%	with	the	nonspecific	NMDA	receptor	blocker	MK-	801,	we	as-







CTD	compared	 to	 human	 (88%	 similarity)	may	 reduce	 the	 validity	
of	the	chicken	model	in	experiments	regarding	downstream	NMDA	
receptor	signaling,	but	as	we	obtained	similar	IC50 values for known 
GluN2B	allosteric	antagonists	in	chicken	that	have	previously	been	
described for rat and human48,52	it	is	most	likely	that	the	human,	rat,	
and chicken receptors share similar functional properties.
The significant differences in IC50 values between the antag-
onists tested suggest different binding properties and these were 
investigated in silico by docking studies and molecular dynamics 
simulations,	predicting	temporal	information	on	the	interactions	be-
tween ligands and binding residues as well as providing details on 
bond	 types.	 As	 no	 experimental	 structures	 of	 NMDA	 receptor	 in	
complex	with	eliprodil	and	Ro	04-	5595	were	available	at	the	time	of	
the	writing,	the	molecular	modeling	approach	gave	new	knowledge	
about the binding properties of these compounds. The only non-
identical	amino	acid	(GluN1Val107	in	the	chicken,	vs	Glun1Ile107	in	
the X. laevis/H. sapiens	crystal	structure)	close	to	both	binding	sites	




probability	 of	 influence	 on	 the	 binding.	None	 of	 the	 ligands	were	
predicted	to	interact	with	GluN1Ile107	so	the	residue	does	not	ap-
pear	 to	 be	 important	 for	 either	 the	 ifenprodil	 or	 EVT-	101	binding	
pocket.
     |  13 of 15FJELLDAL Et AL.
Of	 the	 three	 ligands	 that	 bind	 the	 ifenprodil-	binding	 site,	 Ro	
25-	6981	 and	 ifenprodil	 were	 the	most	 effective	GluN2B	 subunit-	
specific Ca2+	 influx	inhibitors	when	tested	in	the	chicken	forebrain	
primary	 cell	 culture	 assay,	 supported	 by	 the	 work	 of	 Hedegaard	
et	al,48	 in	rat.	Our	in	vitro	experiments	showed	a	significant	differ-
ence in IC50	value	between	Ro	25-	6981	and	ifenprodil	vs	eliprodil,	






inhibitors	 binding	 the	 ifenprodil-	binding	 pocket	 in	 earlier	 publica-
tions.13,17,38,51 Mutel et al18	found	Ro	25-	6981	to	have	larger	affin-
ity to the binding site than both ifenprodil and eliprodil and it might 
be	 suggested	 that	 the	 predicted	 interactions	 with	 GluN1Lys131,	
GluN2BPro78	and	GluN2BLeu205	granted	the	Ro	25-	6981	a	better	





the antagonistic effect of the ligand.
In	silico	docking	of	the	less-	explored	GluN2B-	specific	allosteric	
antagonist	Ro	04-	5595	predicted	that	it	bound	to	the	recently	dis-
covered	 EVT-	101	 binding	 pocket.	 This	 conclusion	 is	 supported	 by	
docking	 studies	 of	 the	 structurally	 similar	 compound	HON000124 
which	 predicted	 that	 HON0001	 would	 bind	 to	 the	 EVT-	101	 site	
as well.17	 The	 analgesic	 effect	 of	 orally	 administrated	 HON0001	
encourages	further	 investigations	of	Ro	04-	5595	as	a	potential	re-
search tool or drug.
The IC50-	values	of	EVT-	101	and	Ro	04-	5595	were	significantly	
different,	with	EVT-	101	as	the	most	effective	antagonist.	Compared	
to	 EVT-	101,	 Ro	 04-	5595	was	 predicted	 to	 interact	more	 strongly	
with	GluN2BPhe114	 and	much	 less	with	GluN2BPhe176,	 and	 this	
is	 supported	by	 the	alanine	 scanning	 results.	 It	 appears	 that	EVT-	
101	 and	 Ro	 04-	5595	 are	 predicted	 to	 interact	with	 different resi-
dues	 to	 a	 larger	 degree	 than	 in	 the	 ifenprodil	 site,	 rather	 than	Ro	
04-	5595	failing	to	interact	with	important	residues,	as	might	be	the	
case with eliprodil. This is supported by the work of Stroebel et al17 
who predicted more diverse binding poses of the ligands docked in 
the	EVT-	101	binding	pocket,	compared	to	the	ligands	docked	in	the	
ifenprodil-	binding	pocket.	EVT-	101	was	predicted	 to	 interact	with	




5595	 supposedly	 interacts	with	GluN1Leu135	 (shared	with	 all	 the	
A-	ligands),	GluN2BPro78	(shared	with	Ro	25-	6981),	GluN2BLys137	
and	GluN2BAsp138	alone,	where	the	interaction	with	the	last	two	
mentioned may be less favorable in terms of causing an inhibiting 
effect on Ca2+influx.	All	of	these	interactions	had	corresponding	al-
anine	mutation	 scanning	 results.	 Earlier	mutagenesis	 experiments	
changing	GluN2BAla135	to	proline,	GluN2BPhe176	to	alanine,	and	
GluN2BPro177	 to	 cysteine	 did	 indeed	 increase	 the	 IC50 value of 
EVT-	101.17
Stroebel et al17	 have	 analyzed	 three	 in	 vitro	 alanine	 muta-
tions.	They	observed	that	in	vitro	mutation	of	GluN1Ile133	led	to	
a lower IC50	value	for	ifenprodil,	and	a	higher	value	for	EVT-	101.	
This corresponded with our in silico observation of higher loss 
of	affinity	for	EVT-	101	than	for	ifenprodil.	However,	mutation	of	
GluN1Leu135	to	alanine	in	vitro, which gave small changes in IC50 
values,	did	not	correspond	with	our	in	silico	alanine	mutation	scan	
results,	which	predicted	a	 reduction	 in	both	 ifenprodil	 and	EVT-	




affinities were predicted to be less affected by this mutation. 
These discrepancies underscore the importance of comparing in 
silico	data	with	experimental	data.
In	 conclusion,	 we	 have	 established	 the	 chicken	 primary	 fore-
brain	 culture	 as	 a	 useful,	 reliable	 and	 convenient	 model	 to	 study	
functional	 properties	 of	 native	 GluN2B-	containing	 NMDA	 recep-
tors,	 giving	 experimental	 support	 to	 in	 silico	 binding	 studies.	 The	
less	investigated	GluN2B-	specific	allosteric	antagonist	Ro	04-	5595	
was	predicted	 to	 interact	with	 the	novel	 EVT-	101	binding	 site,	 an	
interesting pharmaceutical target as it mediates a high degree of 
calcium	influx	inhibition	when	bound.	The	EVT-	101	binding	pocket	





the least potent antagonist.
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